The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000853347
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
23/06/2026
Date registered
Help: Date registered
14/07/2026
Date last updated
Help: Date last updated
14/07/2026
Date data sharing statement initially provided
Help: Data sharing statement date
14/07/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Short vs Prolonged INtervention with Antibiotics for optimaL management of pelvic OsteoMyelitis (SPINAL-OM trial)
Scientific title
Feasibility and Safety of Short (4 weeks) vs. Prolonged (6 weeks) Intervention with Antibiotics for Optimal Management of Pelvic Osteomyelitis
Additional trial identifiers [1] 317673 0
Nil
Universal Trial Number (UTN)
Not applicable
Trial acronym
SPINAL-OM
Related trial records
Not applicable

Health condition
Health condition(s) studied:
Pelvic osteomyelitis 342484 0
Condition category
Condition code
Infection 338611 338611 0 0
Studies of infection and infectious agents
Physical Medicine / Rehabilitation 338612 338612 0 0
Other physical medicine / rehabilitation

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
This is a pilot, feasibility and safety, randomised controlled trial to be conducted in patients admitted to the Victorian Spinal Cord Service at Austin Health in Melbourne, Australia.

Patients with spinal cord injury (SCI) and clinical, radiological, microbiological, or histopathological evidence of osteomyelitis (OM) for multi-disciplinary management will be identified by investigators and assessed for eligibility

Patients in the INTERVENTION group will receive 4 weeks of antibiotic therapy (either intravenous or oral) from date of commencement of effective antibiotic therapy, following surgical source control. Antibiotic therapy will be decided by a treating clinician independent of, and prior to, randomization. The antibiotic therapy will be determined by clinical microbiology and antimicrobial susceptibility data independently of subsequent consent and enrolment in the trial.

Adherence to medication will be monitored using medical administration records during hospitalisation, community dispensing records when in outpatients, and patient reported adherence.
Intervention code [1] 334504 0
Treatment: Drugs
Description of the comparator or control

Patients in the CONTROL group will receive 6 weeks of antibiotic therapy from the date of commencement of effective antibiotic therapy, following surgical source control. The antibiotic therapy (i.e. choice of agent) will be determined by clinical microbiology and antimicrobial susceptibility data independently of subsequent consent and enrolment in the trial
Control group
Active

Outcomes
Primary outcome [1] 345885 0
The primary endpoint will be feasibility of the trial
Timepoint [1] 345885 0
Assessed at D0, 30, 42, 60, 90, 180, 270, 365 Post commencement of intervention (i.e. intitiation of antibiotics after surgical debridement)
Primary outcome [2] 346083 0
The co-primary outcome is safety of the trial
Timepoint [2] 346083 0
To be assessed at D0, 30, 42, 60, 90, 180, 270 and 365 Post commencement of intervention (i.e. initiation of antibiotics after surgical debridement)
Secondary outcome [1] 463625 0
Persistence of infection at same site requiring continuation of antibiotics beyond the planned duration
Timepoint [1] 463625 0
To be assessed at D0, 30, 42, 60, 90, 180, 270 and 365 Post commencement of intervention (i.e. initiation of antibiotics after surgical debridement)
Secondary outcome [2] 463626 0
Recurrence of infection at the same site within the follow-up period
Timepoint [2] 463626 0
To be assessed at D0, 30, 42, 60, 90, 180, 270 and 365 Post commencement of intervention (i.e. initiation of antibiotics after surgical debridement)

Eligibility
Key inclusion criteria
Adult patient 18 years and older with spinal cord injury
Decubitus pressure injury with clinical, radiological, microbiological or histopathological evidence of osteomyelitis.
Planned for multidisciplinary management including surgical debridement, infectious diseases consultation and spinal rehabilitation consultation
Willing and able to consent
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Treating clinician impression of superficial soft tissue infection only, without underlying osteomyelitis

Not appropriate for definitive surgical management within the Spinal Unit (e.g. palliative trajectory, not for operative management).

Concomitant S. aureus bacteraemia

Concomitant septic arthritis without surgical source control

Multifocal areas of osteomyelitis within the pelvis, not amenable to surgical debridement or complete source control

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation is not concealed
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Randomisation will be performed in a 1:1 ratio using a computer-generated permuted block design implemented via REDCap. The allocation sequence will be generated by an independent statistician and will be concealed from study personnel until the point of randomisation. Allocation will be revealed automatically by REDCap at the time of randomisation to ensure allocation concealment.
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis
This is a pilot trial for a future definitive trial, aiming to assess the feasibility and safety of short course therapy in pelvic osteomyelitis in patients with spinal cord injuries. This will also provide local estimates for power calculation in future trials.

We will recruit a total of 80 participants (40/group) as this will provide precise estimates of feasibility outcomes with a total width of 95% CI within 20% for all prevalences. Based on our local experience, we estimate approximately 2 patients per week. Assuming a 50% recruitment rate, this would result in 24 eligible patients in a 6-month month period. Therefore, trial recruitment is likely to be completed within 24 months.


Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC

Funding & Sponsors
Funding source category [1] 322214 0
Charities/Societies/Foundations
Name [1] 322214 0
Marigold Foundation
Country [1] 322214 0
Australia
Primary sponsor type
Hospital
Name
Austin Health
Address
Country
Australia
Secondary sponsor category [1] 325123 0
None
Name [1] 325123 0
Address [1] 325123 0
Country [1] 325123 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320739 0
Austin Health Human Research Ethics Committee
Ethics committee address [1] 320739 0
Ethics committee country [1] 320739 0
Australia
Date submitted for ethics approval [1] 320739 0
02/02/2026
Approval date [1] 320739 0
29/05/2026
Ethics approval number [1] 320739 0
HREC/32052

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 151458 0
Dr Gemma Reynolds
Address 151458 0
Department of Infectious Diseases and Immunology, Level 7 Harold Stokes Building, 145 Studley Road, Heidelberg, VICTORIA, 3084
Country 151458 0
Australia
Phone 151458 0
+61 3 9496 6676
Fax 151458 0
Email 151458 0
Contact person for public queries
Name 151459 0
Fiona James
Address 151459 0
Department of Infectious Diseases and Immunology, Level 7 Harold Stokes Building, 145 Studley Road, Heidelberg, VICTORIA, 3084
Country 151459 0
Australia
Phone 151459 0
+61 3 9496 6676
Fax 151459 0
Email 151459 0
Contact person for scientific queries
Name 151460 0
Gemma Reynolds
Address 151460 0
Department of Infectious Diseases and Immunology, Level 7 Harold Stokes Building, 145 Studley Road, Heidelberg, VICTORIA, 3084
Country 151460 0
Australia
Phone 151460 0
+61 3 9496 6676
Fax 151460 0
Email 151460 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.